IONS
NASDAQIonis Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$43.12-0.42 (-0.96%)
01:30 PM07:00 PM
News · 26 weeks84-50%
2026-04-192026-10-11
Mix2390d
- Other9(39%)
- SEC Filings6(26%)
- Insider5(22%)
- Analyst2(9%)
- Earnings1(4%)
Latest news
25 items- PRTRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the indication extension for TRYNGOLZA® (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). If confirmed by the European Commission (EC), TRYNGOLZA would be the first and only RNA-targeted therapy authorized in the EU for adults with sHTG and triglyceride levels ≥880 mg/dL (≥10 mmol/L). The positive CHMP opinion comes ahead o
- ANALYSTUBS resumed coverage on Ionis Pharma with a new price targetUBS resumed coverage of Ionis Pharma with a rating of Buy and set a new price target of $88.00
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential – – IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation – – Interim data will be presented at an upcoming medical meeting and shared with health authorities – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (
- PRIonis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify disease progression – – Results will be discussed with the U.S. FDA and health authorities globally to enable potential expedited regulatory submission pathways for approval – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with amyotrophic lateral sclerosis (ALS) caused by mutatio
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substantially lower lipoprotein (a) [Lp(a)] levels were achieved with pelacarsen. Elevated Lp(a) is an inherited cardiovascular risk factor affecting approximately one in five people worldwide with no approved targeted treatment. "Although p
- FDAFDA Approval for ZANVASTRO issued to IONIS PHARMS INCSubmission status for IONIS PHARMS INC's drug ZANVASTRO (ORIG-1) with active ingredient ZILGANERSEN has changed to 'Approval' on 09/03/2026. Application Category: NDA, Application Number: 220210, Application Classification: Type 1 - New Molecular Entity
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients- Provides a clinically meaningful impact on motor function and a favorable impact on other symptoms seen in AxD, an ultra-rare, progressive and often fatal neurological disorder - - Priority Review Voucher (PRV) awarded in conjunction with approval - - ZANVASTRO marks Ionis’ first independent launch from its industry-leading neurology pipeline and second independent launch this year - – Ionis to host webcast on Friday, Sept. 4 at 10:00 a.m. ET – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the
- PRIonis to present at upcoming investor conferencesIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Wells Fargo Healthcare Conference on Thursday, September 10, 2026 Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring
- INSIDEREVP, Chief Scientific Officer Bennett C Frank acquired $5,644 worth of shares (110 units at $51.31), increasing direct ownership by 0.18% to 60,128 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERChief Executive Officer Monia Brett P acquired $5,028 worth of shares (98 units at $51.31), increasing direct ownership by 0.04% to 242,760 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDEREVP CLO & General Counsel O'Neil Patrick R. acquired $3,232 worth of shares (63 units at $51.31), increasing direct ownership by 0.11% to 59,205 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDEREVP, Corp and Development Ops Birchler Brian acquired $2,976 worth of shares (58 units at $51.31), increasing direct ownership by 0.06% to 102,883 units (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- PRIonis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich. Presentations include one-year data from the open-label, long-term extension study of TRYNGOLZA® (olezarsen), recently approved in the U.S. as the first and only treatment for sHTG to reduce triglycerides and the risk of acute pancreatitis, and Phase 1 data in hypertriglyceridemia for ION775, an investigational siRNA and next-generation follow-on to TRYNGOLZA with the potential for semiannual or less frequent dosing. "People living with sHTG face th
- ANALYSTBMO Capital Markets initiated coverage on Ionis Pharma with a new price targetBMO Capital Markets initiated coverage of Ionis Pharma with a rating of Market Perform and set a new price target of $60.00
- INSIDERDirector Hayden Michael R bought $1,058,700 worth of shares (20,000 units at $52.94) (SEC Form 4)4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- SECSEC Form S-8 filed by Ionis Pharmaceuticals Inc.S-8 - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECSEC Form 10-Q filed by Ionis Pharmaceuticals Inc.10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- SECIonis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
- PRIonis announces Dr. Frank Bennett, chief scientific officer, to retireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027."As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted medicines," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "Frank’s profound contributions include pioneering the use of antisense medicines in neurological disease. He led the discovery and development of the first approved medicines for spinal muscular atrophy and a genetic form of amyotrophic lateral sclerosis, which have transformed the lives of thousands of people. We are deeply gratef
- PRIonis reports second quarter 2026 financial results and highlights progress on key programs- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome - - On track to achieve 2026 financial guidance - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2026. "With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accele
- INSIDERSEC Form 4 filed by Director Reikes Peter N4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- INSIDERSEC Form 4 filed by Director Hantson Ludwig4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
IONS FAQ
6 questionsWhat does Ionis Pharmaceuticals Inc. do?
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases...Where does IONS stock trade?
Ionis Pharmaceuticals Inc. (IONS) is listed on NASDAQ.What sector and industry is IONS in?
Ionis Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IONS?
Ionis Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-10-15.What companies are similar to IONS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IONS side-by-side with any of them on Quantisnow.How can I track IONS on Quantisnow?
Quantisnow aggregates Ionis Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IONS to receive live email and push alerts on every new disclosure.